Topics:

Zoladex 3-Month Depot Implant Is Approved

Zoladex 3-Month Depot Implant Is Approved

WILMINGTON, Del--Zeneca Pharmaceuticals has received clearance from the FDA to market a new formulation of Zoladex (goserelin acetate implant) for the palliative treatment of advanced prostate cancer.

The new formulation, a 10.8-mg goserelin acetate implant given every 3 months, offers greater convenience to patients choosing treatment with a luteinizing-hormone-releasing hormone (LHRH) analog, the company said.

The original 1-month 3.6-mg formulation of Zoladex implants has been available in the United States since 1989 for the treatment of advanced prostate cancer. The drug has been marketed since 1993 for the treatment of endometriosis, and it was recently cleared by the FDA for the treatment of advanced breast cancer in premenopausal and perimeno-pausal women.

 
Loading comments...
Please Wait 20 seconds or click here to close